Doxefazepam
Chemical compound
- N05CD12 (WHO)
- CA: Schedule IV
- US: Schedule IV
- 9-chloro-6-(2-fluorophenyl)-4-hydroxy-2-(2-hydroxyethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one
- 40762-15-0
N
- 38668
- 35431
Y
- 231RV72C8L
- D07327 Y
- ChEMBL64677 Y
- DTXSID2020551
- Interactive image
- FC1=CC=CC=C1C2=NC(C(N(CCO)C3=C2C=C(C=C3)Cl)=O)O
- InChI=1S/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2Y
- Key:VOJLELRQLPENHL-UHFFFAOYSA-NY
N
Y (what is this?)Doxefazepam (marketed under brand name Doxans) is a benzodiazepine medication It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic.[2] According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.[3]
It was patented in 1972 and came into medical use in 1984.[4]
Side effects
Section 5.5 of the article Doxefazepam in volume 66 of the World Health Organization's (WHO) and International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."[5]
See also
References
- ^ "Doxefazepam". IPCS INTOX. Archived from the original on 24 July 2008.
- ^ Rodriguez G, Rosadini G, Sannita WG, Strumia E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology. 11 (2): 133–139. doi:10.1159/000118066. PMID 6483162.
- ^ Babbini M, Torrielli MV, Strumia E, Gaiardi M, Bartoletti M, De Marchi F (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung. 25 (8): 1294–1300. PMID 241364.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 539. ISBN 9783527607495.
- ^ "Doxefazepam" (PDF). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 66. International Agency For Research On Cancer (IARC): 97–104. 13–20 Feb 1996. PMC 7681544. PMID 9097119. Retrieved 10 July 2014.
External links
- Inchem.org - Doxefazepam
- IARC Monographs - Doxefazepam
- v
- t
- e
- 2-Oxoquazepam
- 3-Hydroxyphenazepam
- Bromazepam
- BMS-906024*
- Camazepam
- Carburazepam
- Chlordiazepoxide
- Cinazepam
- Cinolazepam
- Clonazepam
- Cloniprazepam
- Clorazepate
- Cyprazepam
- Delorazepam
- Demoxepam
- Desmethylflunitrazepam
- Devazepide*
- Diazepam
- Diclazepam
- Difludiazepam
- Doxefazepam
- Elfazepam
- Ethyl carfluzepate
- Ethyl dirazepate
- Ethyl loflazepate
- Flubromazepam
- Fletazepam
- Fludiazepam
- Flunitrazepam
- Flurazepam
- Flutemazepam
- Flutoprazepam
- Fosazepam
- Gidazepam
- Halazepam
- Iclazepam
- Irazepine*
- Kenazepine
- Ketazolam
- Lorazepam
- Lormetazepam
- Lufuradom*
- Meclonazepam
- Medazepam
- Menitrazepam
- Metaclazepam
- Motrazepam
- N-Desalkylflurazepam
- Nifoxipam
- Nimetazepam
- Nitemazepam
- Nitrazepam
- Nitrazepate
- Nordazepam
- Nortetrazepam
- Oxazepam
- Phenazepam
- Pinazepam
- Pivoxazepam
- Prazepam
- Proflazepam
- Quazepam
- QH-II-66
- Reclazepam
- RO4491533*
- Ro05-4082
- Ro5-4864*
- Ro07-5220
- Ro07-9749
- Ro20-8065
- Ro20-8552
- SH-I-048A
- Sulazepam
- Temazepam
- Tetrazepam
- Tifluadom*
- Timelotem*
- Tolufazepam
- Triflunordazepam
- Tuclazepam
- Uldazepam
* atypical activity profile (not GABAA receptor ligands)
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
